Literature DB >> 19158344

Oncostatin M pathway plays a major role in the renal acute phase response.

Valerie A Luyckx1, Lucas V Cairo, Catharine A Compston, Wai Lee Phan, Thomas F Mueller.   

Abstract

The acute phase response is traditionally characterized by hepatic synthesis of proteins as an inflammatory response to injury, with interleukin-6 (IL-6) being the key mediator. In contrast, microarray studies in human renal transplant implantation biopsies indicate a strong acute phase response in the deceased donor kidney, associated with a significant upregulation of oncostatin M receptor beta (OSMR). The aim of this study was to determine whether the kidney can generate a strong acute phase response, mediated by the OSM/OSMR gateway. Genes associated with the IL-6 cytokine family and acute phase reactants were analyzed by real-time RT-PCR in four groups of human biopsies spanning a spectrum of renal injury. OSM, OSMR, and fibrinogen beta (FGB) were progressively more highly expressed from prenephrectomy, living donor, deceased donor, to discarded donor kidneys, suggesting correlation with severity of injury and local renal synthesis. Acute phase response gene expression was analyzed in human proximal tubular cells in culture in response to OSM. OSM induced a significant increase in expression of FGB, OSMR, serpin peptidase inhibitor A1, IL-6, and lipopolysaccharide binding protein, and a decrease in IL-6R. These changes were largely attenuated by coincubation with an OSMR blocking antibody, indicating the OSM effect was mediated through OSMR. OSM also resulted in a significantly altered expression of acute phase genes compared with IL-6 or leukemia inhibitory factor, suggesting that OSM is the predominant cytokine mediating the renal tubular acute phase response. In conclusion, the renal parenchyma is capable of generating a strong acute phase response, likely mediated via OSM/OSMR.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19158344     DOI: 10.1152/ajprenal.90633.2008

Source DB:  PubMed          Journal:  Am J Physiol Renal Physiol        ISSN: 1522-1466


  13 in total

1.  Early differential expression of oncostatin M in obstructive nephropathy.

Authors:  Wafa M Elbjeirami; Luan D Truong; Ahmad Tawil; Wansheng Wang; Sara Dawson; Hui Y Lan; Ping Zhang; Gabriela E Garcia; C Wayne Smith
Journal:  J Interferon Cytokine Res       Date:  2010-07       Impact factor: 2.607

2.  Beyond EMT: Epithelial STAT3 as a Central Regulator of Fibrogenesis.

Authors:  Jeremy S Duffield
Journal:  J Am Soc Nephrol       Date:  2016-07-01       Impact factor: 10.121

3.  Histologic and Molecular Patterns in Responders and Non-responders With Chronic-Active Antibody-Mediated Rejection in Kidney Transplants.

Authors:  Onur Sazpinar; Ariana Gaspert; Daniel Sidler; Markus Rechsteiner; Thomas F Mueller
Journal:  Front Med (Lausanne)       Date:  2022-04-29

4.  Relationships among injury, fibrosis, and time in human kidney transplants.

Authors:  Jeffery M Venner; Konrad S Famulski; Jeff Reeve; Jessica Chang; Philip F Halloran
Journal:  JCI Insight       Date:  2016-01-21

5.  Serial Lipocalin 2 and Oncostatin M levels reflect inflammation status and treatment response in axial spondyloarthritis.

Authors:  Florence W L Tsui; Aifeng Lin; Ismail Sari; Zhenbo Zhang; Hing Wo Tsui; Robert D Inman
Journal:  Arthritis Res Ther       Date:  2021-05-14       Impact factor: 5.156

6.  Synergistic induction of CCL2/MCP-1 expression driven by oncostatin M and IL-1β in human proximal tubular cells depends on STAT3 and p65 NFκB/RelA.

Authors:  Rita Sarközi; Ulrike Corazza; Jan-Philipp Osterkamp; Markus Pirklbauer; Gert Mayer; Herbert Schramek
Journal:  Physiol Rep       Date:  2015-02-22

Review 7.  Host Epigenetics in Intracellular Pathogen Infections.

Authors:  Marek Fol; Marcin Włodarczyk; Magdalena Druszczyńska
Journal:  Int J Mol Sci       Date:  2020-06-27       Impact factor: 5.923

8.  Massive induction of innate immune response to Candida albicans in the kidney in a murine intravenous challenge model.

Authors:  Donna M MacCallum
Journal:  FEMS Yeast Res       Date:  2009-10       Impact factor: 2.796

9.  Safety, tolerability, pharmacokinetics and pharmacodynamics of an anti- oncostatin M monoclonal antibody in rheumatoid arthritis: results from phase II randomized, placebo-controlled trials.

Authors:  Ernest H Choy; Marina Bendit; Dana McAleer; Feng Liu; Maria Feeney; Sara Brett; Stefano Zamuner; Andrea Campanile; John Toso
Journal:  Arthritis Res Ther       Date:  2013-09-24       Impact factor: 5.156

10.  Medial Patellofemoral Ligament Reconstruction Reduces Radiographic Measures of Patella Alta in Adults.

Authors:  Jarret M Woodmass; Nick R Johnson; Robert A Cates; Aaron J Krych; Michael J Stuart; Diane L Dahm
Journal:  Orthop J Sports Med       Date:  2018-01-25
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.